Dr Reddy's Lab launches Remdesivir for Covid-19 treatment in India

News Network

September 9, 2020

Hyderabad, Sept 9: Dr Reddys Laboratories Ltd on Wednesday announced the launch of Remdesivir, meant for the treatment of Covid-19 patients, under a brand name 'Redyx' in India.

According to a press release from the drug maker, the launch is part of the licensing agreement with Gilead Sciences, Inc. (Gilead) that grants Dr Reddys the right to register, manufacture and sell Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Remdesivir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of Covid-19 patients hospitalized with severe symptoms.

"Dr Reddy's Redyx is available in strength of 100 mg vial," it said. Chief Executive Officer of Branded Markets (India and Emerging Markets),

Dr Reddys Laboratories, M V Ramana said, "We will continue our efforts to develop products that address significant unmet needs of patients. The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from Covid-19 in India."

Comments

Add new comment

Coastaldigest.com reserves the right to delete or block any comments.
Coastaldigset.com is not responsible for its readers’ comments.
Comments that are abusive, incendiary or irrelevant are strictly prohibited.
Please use a genuine email ID and provide your name to avoid reject.

Will end Karnataka leadership confusion after talks with top leaders: Kharge

News Network

November 27,2025

Congress president Mallikarjun Kharge on Thursday announced that he will convene a high-level meeting in New Delhi with senior leaders — including Rahul Gandhi, Karnataka Chief Minister Siddaramaiah and Deputy Chief Minister D.K. Shivakumar — to resolve the escalating leadership turmoil in Karnataka and “put an end to the confusion.”

Kharge said the discussions would focus on the way forward for the ruling party, as rumours of a possible leadership change continue to swirl. The speculation has intensified after the Congress government crossed the halfway mark of its five-year term on November 20, reviving talk of an alleged 2023 “power-sharing agreement” between Siddaramaiah and Shivakumar.

“After reaching Delhi, I will call three or four important leaders and hold discussions. Once we talk, we will decide how to move ahead and end this confusion,” Kharge told reporters in Bengaluru, according to PTI.

When asked specifically about calling Siddaramaiah and Shivakumar to Delhi, he responded: “Certainly, we should call them. We will discuss with them and settle the issue.”

He confirmed that Rahul Gandhi, the Chief Minister, the Deputy Chief Minister and other senior members would be part of the deliberations. “After discussing with everyone, a decision will be made,” he said.

Meanwhile, Siddaramaiah held a separate strategy meeting at his Bengaluru residence with ministers and leaders seen as his close confidants, including G. Parameshwara, Satish Jarkiholi, H.C. Mahadevappa, K. Venkatesh and K.N. Rajanna.
Signalling calm, the Chief Minister told reporters, “Will go to Delhi if the high command calls.”

Shivakumar echoed a similar stance, saying he too would head to the national capital if summoned by the party leadership.

Comments